Tussionex Articles
Belgium’s UCB posts disappointing 2009 results, but projects better future based on newer drugs
3 March 2010
Belgium’s UCB to maximize US focus and resources on core products, hiving off primary care to Sanofi and Teva
1 February 2010
UCB revenue falls on drop in US sales
1 May 2009
UCB absorbs Zyrtec patent expiry, but 2008 profit still down 74% on restructuring charges
9 March 2009
FDA issues warning on UCB's cough medicine
24 March 2008
Celltech sees sales rise 6% in 2003
22 March 2004
UPDATE- Pretax profits up at Celltech in 2002
24 March 2003
Celltech pretax profits leap 90%
18 March 2002
Medeva confident about its future
12 February 1999
UK's Medeva Redefining Product Portfolio
18 February 1998
Strong Growth In 1996 As Medeva Builds In the USA
24 February 1997
Concerns Around Medeva Acquisition
24 June 1996
Showing 1-12 of 12 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
